Pre-treatment with glucagon-like peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization

JACC: Cardiovascular Interventions

Volumn 8, Issue 2, 2015, Pages 292-301

  McCormick, Liam M ^a   Hoole, Stephen P ^b   White, Paul A ^c   Read, Philip A ^b   Axell, Richard G ^c   Clarke, Sophie J ^a   O'Sullivan, Michael ^b   West, Nick E J ^b   Dutka, David P ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b PAPWORTH HOSPITAL   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

angioplasty; cardioprotection; glucagon like peptide 1; myocardial ischemia; myocardial stunning; myocardial substrate use

Indexed keywords

FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; INCRETIN;

ARTICLE; BALLOON OCCLUSION; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORONARY HEMODYNAMICS; CORONARY SINUS; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HEART CATHETER; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PERFORMANCE; HEART MUSCLE METABOLISM; HEART PROTECTION; HEART STROKE VOLUME; HUMAN; INFUSION; INSULIN BLOOD LEVEL; ISCHEMIC HEART DISEASE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPERFUSION; STUNNED HEART MUSCLE; CORONARY DISEASE; HEART CATHETERIZATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIAL STUNNING; PREVENTION AND CONTROL; TREATMENT OUTCOME;

CARDIAC CATHETERIZATION; CORONARY DISEASE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIAL STUNNING; PERCUTANEOUS CORONARY INTERVENTION; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84923165949     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2014.09.014     Document Type: Article

References (33)

1. J.J. Holst The physiology of glucagon-like peptide 1 Physiol Rev 87 2007 1409 1439
2. L.L. Baggio, and D.J. Drucker Biology of incretins: GLP-1 and GIP Gastroenterology 132 2007 2131 2157
3. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, and M. Husain Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 117 2008 2340 2350
4. A.K. Bose, M.M. Mocanu, R.D. Carr, C.L. Brand, and D.M. Yellon Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury Diabetes 54 2005 146 151
5. A.K. Bose, M.M. Mocanu, R.D. Carr, and D.M. Yellon Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model Cardiovasc Drugs Ther 19 2005 9 11
6. A.K. Bose, M.M. Mocanu, R.D. Carr, and D.M. Yellon Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway Cardiovasc Drugs Ther 21 2007 253 256
7. L.A. Nikolaidis, S. Mankad, and G.G. Sokos Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 2004 962 965
8. J. Lonborg, N. Vejlstrup, and H. Kelbaek Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction Eur Heart J 33 2012 1491 1499
9. P.A. Read, S.P. Hoole, and P.A. White A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans Circ Cardiovasc Interv 4 2011 266 272
10. P.A. Read, F.Z. Khan, P.M. Heck, S.P. Hoole, and D.P. Dutka DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease Circ Cardiovasc Imaging 3 2010 195 201
11. P.A. Read, F.Z. Khan, and D.P. Dutka Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease Heart 98 2012 408 413
12. L.M. McCormick, A.C. Kydd, and P.A. Read Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease Circ Cardiovasc Imaging 7 2014 274 281
13. S.P. Hoole, P.M. Heck, and P.A. White Stunning and cumulative left ventricular dysfunction occurs late after coronary balloon occlusion in humans: insights from simultaneous coronary and left ventricular hemodynamic assessment J Am Coll Cardiol Intv 3 2010 412 418
14. K. Thygesen, J.S. Alpert, and A.S. Jaffe Third universal definition of myocardial infarction J Am Coll Cardiol 60 2012 1581 1598
15. J. Baan, E.T. van der Velde, and H.G. de Bruin Continuous measurement of left ventricular volume in animals and humans by conductance catheter Circulation 70 1984 812 823
16. P.G. Nelson Effect of heparin on serum free-fatty-acids, plasma catecholamines, and the incidence of arrhythmias following acute myocardial infarction Br Med J 3 1970 735 737
17. S. Ravassa, A. Zudaire, and J. Diez GLP-1 and cardioprotection: from bench to bedside Cardiovasc Res 94 2012 316 323
18. S.J. Clarke, L.M. McCormick, and D.P. Dutka Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1 Cardiovasc Diabetol 13 2014 12
19. W.C. Stanley, G.D. Lopaschuk, J.L. Hall, and J.G. McCormack Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions Cardiovasc Res 33 1997 243 257
20. L.A. Nikolaidis, D. Elahi, and T. Hentosz Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy Circulation 110 2004 955 961
21. W. Bao, K. Aravindhan, and H. Alsaid Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency PLoS One 6 2011 e23570
22. M. Kavianipour, M.R. Ehlers, and K. Malmberg Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium Peptides 24 2003 569 578
23. S.P. Moberly, K.J. Mather, and Z.C. Berwick Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus Basic Res Cardiol 108 2013 365
24. M. Gejl, S. Lerche, and A. Mengel Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo- or hypoglycemia PLoS One 9 2014 e83758
25. M. Gejl, H.M. Sondergaard, and C. Stecher Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes J Clin Endocrinol Metab 97 2012 E1165 E1169
26. R.M. Witteles, K.V. Keu, A. Quon, H. Tavana, and M.B. Fowler Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy J Card Fail 18 2012 804 809
27. W.C. Stanley, J.L. Hall, C.K. Stone, and T.A. Hacker Acute myocardial ischemia causes a transmural gradient in glucose extraction but not glucose uptake Am J Physiol 262 1992 H91 H96
28. K. Peuhkurinen, M. Ikaheimo, J. Airaksinen, H. Huikuri, M. Linnaluoto, and J. Takkunen Changes in myocardial energy metabolism in elective coronary angioplasty Cardiovasc Res 25 1991 158 163
29. D.J. Hausenloy, H.J. Whittington, and A.M. Wynne Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner Cardiovasc Diabetol 12 2013 154
30. M. Ovize, K. Przyklenk, S.L. Hale, and R.A. Kloner Preconditioning does not attenuate myocardial stunning Circulation 85 1992 2247 2254
31. D.P. Jenkins, W.B. Pugsley, and D.M. Yellon Ischaemic preconditioning in a model of global ischaemia: infarct size limitation, but no reduction of stunning J Mol Cell Cardiol 27 1995 1623 1632
32. S.P. Hoole, S.N. Khan, and P.A. White Remote ischaemic pre-conditioning does not attenuate ischaemic left ventricular dysfunction in humans Eur J Heart Fail 11 2009 497 505
33. C. Depre, J.L. Vanoverschelde, and H. Taegtmeyer Glucose for the heart Circulation 99 1999 578 588